Kalaris Therapeutics Inc KLRS
$4.15 $0.03 (0.73%) 1D
Last Updated: Aug 21, 12:00 AM·NASDAQ
Pricing for US stocks is delayed by 24 hours
KLRS Shariah Compliance
Screening Methodology: AAOIFI
As of August 2026, Kalaris Therapeutics Inc is classified as not halal.
NOT HALAL
Report Source: undefined Quarter Report
Kalaris Therapeutics Inc. Stock Analysis KLRS
United States Health Care Micro Cap Kalaris Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics for retinal diseases. The company is headquartered in Berkeley Heights, New Jersey and currently employs 20 full-time employees. The company went IPO on 2020-07-30. The firm is focused on the development of TH103, a differentiated anti-vascular endothelial growth factor (VEGF) investigational therapy. TH103 is a fully humanized, recombinant fusion protein that acts against VEGF as a decoy receptor and has been specifically engineered for potentially improved VEGF inhibition and longer retention in the retina. TH103 is being evaluated in an ongoing, Phase I clinical trial for the treatment of neovascular age-related macular degeneration (nAMD), with plans to develop TH103 for additional neovascular and exudative diseases of the retina such as diabetic macular edema (DME), and retinal vein occlusion (RVO).
Kalaris Therapeutics Inc (KLRS) Chart
Financial Metrics & Statements of Kalaris Therapeutics Inc (KLRS)
FAQ's for Kalaris Therapeutics Inc (KLRS)
- As of August 2026, Kalaris Therapeutics Inc KLRS is classified as not halal according to Musaffa’s Shariah screening methodology. This classification is based on an assessment of the company’s business activities and financial ratios against Islamic investment guidelines.
- A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Kalaris Therapeutics Inc using these criteria to determine its compliance status.
- Muslim investors may consider investing in Kalaris Therapeutics Inc if it meets Shariah compliance standards. Investors typically review the company’s business activities, debt levels, and non-permissible income before making a decision.
- Musaffa determines the Shariah status of Kalaris Therapeutics Inc by analyzing whether the company’s core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.
- The Shariah compliance status of Kalaris Therapeutics Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.
- Yes. A stock that is currently Shariah-compliant may become non-compliant if the company’s financial ratios exceed Shariah thresholds or its business activities change.
- You can check the latest Shariah compliance status of Kalaris Therapeutics Inc on Musaffa’s stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.
Alternate Halal Stocks for Kalaris Therapeutics Inc (KLRS)
Related Halal Stocks are Shariah-compliant companies that align with Islamic investment principles, avoiding prohibited industries like alcohol, gambling, and interest-based finance.
